Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeneFIX prophylaxis versus on-demand treatment in severe hemophilia B
2005-005246-40Phase 3Completed
- Sponsor
- Wyeth
- Start
- Oct 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of coagulation factor ix recombinant in hemophilia B (HB) (3 arms), sponsored by Wyeth. Primary endpoint: Primary efficacy and safety comparison of prophylaxis versus on-demand treatment. Started Oct 2006; status: completed.
02
Drugs
coagulation factor ix recombinant
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2005-005246-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005246-40.